Does Oxytocin Alter Tolerance to or Motivation for Alcohol
A legfontosabb adatok
- Ki végzi
- Indiana University
- Hol
- Indianapolis (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 6 fő vett részt
- Kezdés
- 2022. jan. 16.
- Befejezés
- 2023. dec. 21.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Intranasal oxytocin
- Intranasal placebo
- A regiszteradat frissítve
- 2025. március 4.
- Miért állt le
- Due to complications delaying the availability of the intranasal oxytocin and IV alcohol solutions needed for this project, we were unable to complete subjects in the self-administration arm of this study.
Ki vehet részt
- Életkor
- 21 év – 60 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Heavy alcohol drinkers
- Able to understand/complete questionnaires and procedures in English
- Have venous access sufficient to allow blood sampling
Ki nem vehet részt
- Positive urine drug screen for amphetamines/ methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine if determined by the PI to adversely affect participant safety or data integrity
- Medications (past 30 days) that could influence participant safety or data integrity (e.g. antidepressants, antipsychotics, benzodiazepines, etc.) as determined by the PI
- Latex allergy
- Nasal condition that compromises delivery and/or absorption of intra-nasal oxytocin
- Desire to be treated for any substance use disorder or court ordered to not drink alcohol
- Medical disorders or other conditions such as alcohol withdrawal seizures or delirium tremens that may influence study outcome or participant safety
- DSM 5 Disorders (other than alcohol) or current/history of neurological disease of cerebral origin, or head injury with > 20 min loss of consciousness, if determined by the PI to affect participant safety or data integrity
- Any condition for which the PI and investigative team determine it is unsafe or not prudent to enroll a participant
- Pregnant or breast-feeding women
- Positive breath alcohol reading at beginning of the experimental session
- Actively suicidal (for example, any current suicidal intent, including a plan) or are at serious suicidal risk, by clinical judgment of the PI
Helyszínek itt: Egyesült Államok
- University HospitalIndianapolis, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This pilot study is intended to demonstrate feasibility and acquire preliminary data. If successful, this data could support a future project studying the effect of oxytocin on tolerance and alcohol seeking in humans.
A vizsgálat 2 csoportja
- ClampA vizsgált kezelés
Repeated subjective and cognitive tests during a 4 hour session that includes a baseline period, an oxytocin or placebo delivery, absorption and testing period, and a 2 hour alcohol clamp. Oxytocin or placebo were delivered intranasally in two sessions, scheduled 3-4 weeks apart, double blind.
Kezelés: Intranasal oxytocin és Intranasal placebo
- Progressive work for alcoholA vizsgált kezelés
Progressive work alcohol exposure, 2 sessions (intranasal oxytocin or placebo), double blind. Note this Arm was not completed (see Overall Status for explanation of study termination)
Kezelés: Intranasal oxytocin és Intranasal placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Does Oxytocin Alter Tolerance to Alcohol or Motivation for Alcohol in Heavy Drinking Human Subjects: Testing a Novel Anti-Addiction Mechanism
- A regiszteradat frissítve
- 2025. március 4.